GSK and iTeos anti-TIGIT antibody belrestotug showed efficacy in a phase 2 trial in PD-L1-positive non-small cell lung cancer (NSCLC), providing some much-needed positive news for the belea
Bristol-Myers Squibb has handed back rights to a TIGIT drug partnered with Agenus, ending an alliance that could have been worth up to $1.56 billion to the biotech.